GT Biopharma
GTBP
16 hedge funds and large institutions have $711K invested in GT Biopharma in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
223% more capital invested
Capital invested by funds: $220K → $711K (+$491K)
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
23% more funds holding
Funds holding: 13 → 16 (+3)
2.39% more ownership
Funds ownership: 3.92% → 6.31% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$201K |
| 2 |
Renaissance Technologies
New York
|
+$68K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$22.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.4K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$2.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$45.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.23K |
| 3 |
GIA
GHP Investment Advisors
Denver,
Colorado
|
-$71 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$65 |
| 5 |
FFA
Farther Finance Advisors
San Francisco,
California
|
-$14 |
GTBP Hedge Fund Activity: Q2 2025 in Review
16 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2025, worth a combined $711K — up 223% from $220K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GTBP positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Bank of Montreal, adding an estimated $201K. The largest seller was Citadel Advisors, exiting entirely with an estimated $45.1K sold.
- 16 institutional investors held GT Biopharma (GTBP) as of Q2 2025, up from 13 in Q1 2025.
- Funds reported $711K of GT Biopharma stock for Q2 2025, up 223% quarter-over-quarter.
- 5 funds opened new GT Biopharma positions in Q2 2025 and 2 closed out, a net change of +3 holders.
- The largest GT Biopharma buyer in Q2 2025 was Bank of Montreal, an estimated $201K added.
- The largest GT Biopharma seller in Q2 2025 was Citadel Advisors, an estimated $45.1K sold.
Based on aggregated 13F filings for Q2 2025.